Nexus Neurotech

Nexus Neurotech is a venture capital firm established in 2023 and located in San Francisco, California. The firm specializes in investing in medical technology companies, focusing on innovative solutions that enhance healthcare outcomes. By providing financial support and strategic guidance, Nexus Neurotech aims to foster the growth of emerging technologies in the medical field, contributing to advancements in patient care and treatment options.

Jordi Parramon

Co-Founder, CEO and General Partner

6 past transactions

Nobi

Series B in 2025
Nobi is a smart lamp that ensures help can be provided in a flash in the event of a fall. It recognizes a fall, and it will notify a family member, contacts, or a specialized emergency call center. The lamp will then connect to that person to reassure them that help is on the way. If necessary, it can even unlock the smart lock on the front door.

Cala Health

Series C in 2024
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

Cortica

Venture Round in 2024
Cortica Inc. is a company dedicated to providing neurological therapies for children facing autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers tailored treatment programs that are informed by a comprehensive understanding of each child's neurobiology and developmental profile. The company operates multiple centers across California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village. Cortica's services encompass a wide range of assessments and therapies, including diagnoses for autism, ADHD, and developmental delays. Treatment options available include gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and various therapeutic interventions such as ABA therapy, parent coaching, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company provides these services through in-home, in-clinic, and telehealth modalities.

Synapticure

Series A in 2024
Synapticure is a virtual clinical care platform dedicated to supporting patients with neurodegenerative diseases, including dementia, Parkinson's, and ALS, throughout the United States. Founded by patients, the company offers comprehensive care services that include access to disease-specific neurologists, speech and language therapy, and 24/7 care coordination. Utilizing advances in science, technology, and computational analytics, Synapticure ensures that patients receive tailored treatment and support in their own homes. The platform integrates medical, dental, vision, and life insurance plans to facilitate easy access to a range of healthcare services, including behavioral health support such as psychiatry and therapy, all aimed at enhancing the quality of life for individuals facing these challenging conditions.

EarliTec Diagnostics

Series B in 2024
EarliTec Diagnostics is a digital health company focused on the early identification and treatment of autism spectrum disorder (ASD) and related disabilities in children. The company was developed by prominent researchers from Children’s Healthcare of Atlanta, Emory University School of Medicine, and Yale University. EarliTec is at the forefront of creating biomarkers that provide insights into how children perceive their environment. Its innovative technology utilizes dynamic quantification of social-visual engagement (DQSVE) to monitor looking behavior that is often undetectable to the naked eye. This capability enables parents, providers, and caregivers to implement personalized and timely therapeutic interventions for children.

Rune Labs

Venture Round in 2024
Rune Labs, Inc. is a San Francisco-based company that develops a software-as-a-service platform focused on neuromodulation systems to enhance the management of complex therapies. Founded in 2018, the platform processes brain imaging and electrophysiology data from clinical studies and patient care, making it valuable for neuroscience therapeutics. It supports pharmaceutical companies in creating and implementing precision therapies for conditions such as Parkinson's disease, epilepsy, depression, and obsessive-compulsive disorder. The cloud-based platform allows therapy developers to efficiently manage data and run complex algorithms across multiple patients, facilitating the delivery of precision medicine and identifying potential responders for clinical trials. By integrating with emerging neuromodulation devices, Rune Labs enables clients to leverage large datasets for therapy development and adaptive therapy applications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.